Syra Health Corp. Class A (SYRA) AI Stock Analysis

• Market Cap: $1.10M
• Dividend Yield: N/A
• Average Volume (3M): 9.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -3.14%
• EPS Growth: 81.98%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 11,339,169
• 10 Day Avg. Volume: 11,249
• 30 Day Avg. Volume: 9,759
• PEG Ratio: 0.06
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.37
• P/FCF Ratio: -1.02
• Enterprise Value/Market Cap: -0.75
• Enterprise Value/Revenue: -0.11
• Enterprise Value/Gross Profit: -0.35
• Enterprise Value/Ebitda: 0.67
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.08 ▼(-6.67% Downside)

The score is primarily constrained by weak financial performance—ongoing losses and negative operating/free cash flow—despite improving margins and reduced leverage. Technicals are neutral with the price still below the 200-day average, and valuation offers limited support due to negative earnings. A positive CEO appointment provides a modest offset but is not yet evidenced in results.

Positive Factors

Leadership Upgrade — New CEO

Appointment of a CEO with deep Medicare/Medicaid and population-health experience is a structural capability boost. Over months this should improve contract win rates, execution on government programs and strategic partnerships, aligning management skills with Syra’s target markets.

Improving Profitability Trends

Material margin expansion and a much smaller net loss margin reflect improving unit economics and tighter cost control. If sustained, higher gross margins enable operating leverage as revenue stabilizes, shortening the path to sustainable profitability and reinvestment capacity.

Manageable Leverage

Low leverage reduces interest burden and financial distress risk, giving the company flexibility to invest in program delivery and sales to win government contracts. Improved capital structure versus 2022 (>1x) provides a more durable runway while cash flow recovery is pursued.

Negative Factors

Ongoing Unprofitability

Persistent negative operating profit and net losses weaken internal funding, can erode equity over time, and limit reinvestment. Until operating profitability is achieved, growth initiatives depend on external capital which constrains long-term strategic independence and scale.

Negative Cash Generation

Ongoing negative operating and free cash flow means the business is not yet self-funding and remains reliant on financing or balance-sheet resources. This limits ability to invest in technology, staffing, or contract expansion and increases vulnerability to liquidity shocks.

Revenue Contraction

A multi-period revenue decline undermines scale advantages and makes fixed-cost absorption harder, slowing margin recovery. For a services firm dependent on government contracts, shrinking revenue raises questions about contract retention and competitive positioning over the next several quarters.

Syra Health Corp. Class A Business Overview & Revenue Model

Company Description

Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.

How the Company Makes Money

Syra Health Corp. generates revenue primarily through its subscription-based model for its digital health platforms, where healthcare providers pay a recurring fee for access to its technology and services. Additionally, the company earns income from transaction fees related to telemedicine consultations and data analytics services. Strategic partnerships with healthcare organizations and technology firms further enhance its revenue streams by enabling joint offerings and expanding market reach. The company's focus on improving operational efficiency for healthcare providers translates into cost savings, making its solutions attractive, which in turn drives customer acquisition and retention.

Syra Health Corp. Class A Financial Statement Overview

Summary

Results show improvement but remain weak overall: TTM revenue declined (~7%), the company is still unprofitable (negative operating profit and net income), and operating/free cash flow are still negative (cash burn), despite materially better margins and a much smaller loss in the most recent period. Balance sheet leverage is currently modest versus equity, which helps, but ongoing losses remain the primary risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined (~7%), but profitability improved materially versus prior annual periods: gross margin rose to ~31% (from ~21% in 2024) and the net loss margin narrowed to about -17% (from roughly -47% in 2024 and worse in 2022–2023). The key weakness remains ongoing losses (negative operating profit and net income), indicating the business has not yet reached sustainable profitability despite the improvement.

Balance Sheet

Leverage looks manageable in the most recent periods, with low debt relative to equity in TTM (Trailing-Twelve-Months) (~0.11) and 2024 (~0.16), and equity remains positive. This is a meaningful improvement from 2022 when debt was high versus equity (>1x). The main concern is continued negative returns on equity (loss-making), which can erode the equity base over time if losses persist.

Cash Flow

Cash generation remains a weak point: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are still negative (about -$0.23M), and 2024 was significantly worse (roughly -$2.9M). While cash burn appears to have improved sharply in the most recent period, the company is not yet self-funding and remains reliant on external capital or balance sheet resources until cash flow turns positive.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.50M	7.98M	5.52M	5.62M	1.41M	0.00
Gross Profit	2.35M	1.65M	1.41M	1.06M	430.35K	0.00
EBITDA	-1.23M	-3.68M	-2.84M	-2.07M	-3.07K	-4.27K
Net Income	-1.27M	-3.76M	-2.94M	-2.12M	-3.28K	-4.27K
Balance Sheet
Total Assets	3.26M	3.68M	4.92M	2.32M	536.89K	3.00K
Cash, Cash Equivalents and Short-Term Investments	1.98M	2.40M	3.28M	3.34K	100.01K	3.00K
Total Debt	232.35K	452.08K	248.10K	934.84K	342.86K	3.00K
Total Liabilities	1.05M	800.76K	910.07K	1.61M	544.04K	7.17K
Stockholders Equity	2.21M	2.88M	4.01M	710.10K	-7.15K	-4.17K
Cash Flow
Free Cash Flow	-231.03K	-2.94M	-2.77M	-2.37M	-94.49K	0.00
Operating Cash Flow	-231.03K	-2.93M	-2.76M	-2.24M	-88.20K	0.00
Investing Cash Flow	0.00	-11.11K	-15.25K	-121.26K	-6.29K	0.00
Financing Cash Flow	-372.49K	2.06M	6.05M	2.27M	191.50K	36.00K

Syra Health Corp. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.53 is Neutral, neither overbought nor oversold. The STOCH value of 35.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.

Syra Health Corp. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$14.32M	-6.41	-8.75%	―	17.84%	-156.13%
SYRA	48 Neutral	$1.10M	-0.79	-45.71%	―	-3.14%	81.98%
CCM	44 Neutral	$17.24M	-0.76	―	―	-22.38%	56.66%
CCEL	44 Neutral	$26.90M	-56.42	―	11.14%	-0.29%	94.56%
PIII	43 Neutral	$13.91M	-0.04	-257.39%	―	-2.15%	-6.72%

Syra Health Corp. Class A Corporate Events

Syra Health Appoints Gregory Alexander as New CEO

On December 15, 2025, Syra Health’s board appointed healthcare executive and former U.S. Marine officer Gregory R. Alexander as chief executive officer, with his employment agreement and compensation package, including salary, bonus eligibility, equity grants and change-of-control severance protections, set to take effect on January 5, 2026. Announced publicly on December 18, 2025, the appointment brings in a seasoned growth-focused leader with extensive Medicare, Medicaid and population health experience, reflecting Syra Health’s bid to accelerate expansion in its core markets and signaling a strategic move to strengthen execution and value creation for customers, shareholders and the communities it serves.

The most recent analyst rating on (SYRA) stock is a Hold with a $0.06 price target. To see the full list of analyst forecasts on Syra Health Corp. Class A stock, see the SYRA Stock Forecast page.

Syra Health Corp. Amends Certificate of Incorporation

On November 14, 2025, Syra Health Corp.’s stockholders approved amendments to the company’s Certificate of Incorporation, which included the removal of an automatic conversion clause for Class B Common Stock upon the death of a stockholder and allowed transfers to immediate family members without conversion. The amendments were filed and became effective on November 18, 2025, potentially impacting the company’s stockholder structure and transferability of shares.

Syra Health Corp. Approves Key Amendments at Annual Meeting

On November 14, 2025, Syra Health Corp. held its Annual Meeting of Stockholders where several key decisions were made. All five nominees for the board of directors were elected to serve until the next annual meeting, and the appointment of M&K CPAs, PLLC as the independent accounting firm was ratified. Additionally, amendments to the company’s Certificate of Incorporation were approved, including the removal of automatic conversion of Class B stock upon a stockholder’s death and allowing transfers to family members without conversion.